Compounds > temozolomide
Page last updated: 2024-11-04

temozolomide and Cancer of Lung

temozolomide has been researched along with Cancer of Lung in 109 studies

Research Excerpts

ExcerptRelevanceReference
"This alternating weekly, dose-dense temozolomide regimen was well tolerated and clinically active in heavily pretreated patients with brain metastases, particularly in patients with melanoma."9.14Dose-dense temozolomide regimen for the treatment of brain metastases from melanoma, breast cancer, or lung cancer not amenable to surgery or radiosurgery: a multicenter phase II study. ( Bajetta, E; Cascinu, S; Crinò, L; Danova, M; Del Prete, S; Salvagni, S; Schiavetto, I; Siena, S; Vitali, M, 2010)
"The objective of this study was to evaluate the activity and toxicity of temozolomide given as an extended schedule in patients with advanced sarcoma."9.11A phase II trial of temozolomide as a 6-week, continuous, oral schedule in patients with advanced soft tissue sarcoma: a study by the Spanish Group for Research on Sarcomas. ( Bover, I; Buesa, JM; Casado, A; Cruz, J; Garcia del Muro, X; Lopez-Pousa, A; Martin, J; Martinez-Trufero, J; Maurel, J; Poveda, A, 2005)
"A multicentre, centrally randomized, open-labelled study with temozolomide and interferon (IFN)-alpha 2b was carried out to study the therapeutic effect in patients with metastatic melanoma stage IV."9.11Temozolomide and interferon alpha 2b in metastatic melanoma stage IV. ( Fialla, R; Forstinger, Ch; Fritsch, P; Hofmann-Wellenhof, R; Kehrer, H; Kerl, H; Kindermann-Glebowski, E; Klein, G; Koller, J; Konrad, K; Kos, C; Lang, A; Mischer, P; Pachinger, W; Pehamberger, H; Raml, J; Ratzinger, G; Richtig, E; Seeber, A; Smolle, J; Steiner, A; Ulmer, H; Wolff, K; Zelger, B, 2004)
"Temozolomide has shown efficacy in the treatment of metastatic melanoma similar to that of dacarbazine (DTIC), the standard chemotherapy, but with the added benefit of penetration into the central nervous system (CNS)."9.10Effect of temozolomide on central nervous system relapse in patients with advanced melanoma. ( Brampton, MH; Calvert, AH; Middleton, MR; Paul, MJ; Rustin, G; Summers, Y; Thatcher, N, 2002)
"Temozolomide is a rapidly absorbed chemotherapeutic agent, achieving significant central nervous system penetration."6.72Alternating chemo-immunotherapy with temozolomide and low-dose interleukin-2 in patients with metastatic melanoma. ( Hansson, J; Månsson-Brahme, E; Masucci, GV; Nilsson, B; Ragnarsson-Olding, B; Wagenius, G, 2006)
"The standard treatment for brain metastases is radiotherapy."6.55Combined treatment for non-small cell lung cancer and breast cancer patients with brain metastases with whole brain radiotherapy and temozolomide: a systematic review and meta-analysis. ( Luo, Y; Tang, J; Tian, J; Xiang, J, 2017)
"This alternating weekly, dose-dense temozolomide regimen was well tolerated and clinically active in heavily pretreated patients with brain metastases, particularly in patients with melanoma."5.14Dose-dense temozolomide regimen for the treatment of brain metastases from melanoma, breast cancer, or lung cancer not amenable to surgery or radiosurgery: a multicenter phase II study. ( Bajetta, E; Cascinu, S; Crinò, L; Danova, M; Del Prete, S; Salvagni, S; Schiavetto, I; Siena, S; Vitali, M, 2010)
"The objective of this study was to evaluate the activity and toxicity of temozolomide given as an extended schedule in patients with advanced sarcoma."5.11A phase II trial of temozolomide as a 6-week, continuous, oral schedule in patients with advanced soft tissue sarcoma: a study by the Spanish Group for Research on Sarcomas. ( Bover, I; Buesa, JM; Casado, A; Cruz, J; Garcia del Muro, X; Lopez-Pousa, A; Martin, J; Martinez-Trufero, J; Maurel, J; Poveda, A, 2005)
"A multicentre, centrally randomized, open-labelled study with temozolomide and interferon (IFN)-alpha 2b was carried out to study the therapeutic effect in patients with metastatic melanoma stage IV."5.11Temozolomide and interferon alpha 2b in metastatic melanoma stage IV. ( Fialla, R; Forstinger, Ch; Fritsch, P; Hofmann-Wellenhof, R; Kehrer, H; Kerl, H; Kindermann-Glebowski, E; Klein, G; Koller, J; Konrad, K; Kos, C; Lang, A; Mischer, P; Pachinger, W; Pehamberger, H; Raml, J; Ratzinger, G; Richtig, E; Seeber, A; Smolle, J; Steiner, A; Ulmer, H; Wolff, K; Zelger, B, 2004)
"Temozolomide has shown efficacy in the treatment of metastatic melanoma similar to that of dacarbazine (DTIC), the standard chemotherapy, but with the added benefit of penetration into the central nervous system (CNS)."5.10Effect of temozolomide on central nervous system relapse in patients with advanced melanoma. ( Brampton, MH; Calvert, AH; Middleton, MR; Paul, MJ; Rustin, G; Summers, Y; Thatcher, N, 2002)
" Two compounds in this series were found to potentiate the cytotoxicity of the DNA-methylating agent temozolomide by 4-5-fold in a human colorectal cancer cell line."3.72Potentiation of cytotoxic drug activity in human tumour cell lines, by amine-substituted 2-arylbenzimidazole-4-carboxamide PARP-1 inhibitors. ( Curtin, NJ; Eastman, BW; Golding, BT; Griffin, RJ; Hostomsky, Z; Kyle, S; Li, J; Maegley, KA; Skalitzky, DJ; Webber, SE; White, AW; Yu, XH, 2004)
" The biological effects of two novel PARP inhibitors, NU1025 (8-hydroxy-2-methylquinazolin-4-[3H]one, Ki = 48 nM) and NU1085 [2-(4-hydroxyphenyl)benzamidazole-4-carboxamide, Ki = 6 nM], in combination with temozolomide (TM) or topotecan (TP) have been studied in 12 human tumor cell lines (lung, colon, ovary, and breast cancer)."3.70Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines. ( Calvert, AH; Curtin, NJ; Delaney, CA; Durkacz, BW; Hostomsky, Z; Kyle, S; Newell, DR; Wang, LZ; White, AW, 2000)
" In melanoma specimens taken from a patient 3 h post-treatment with temozolomide, MGMT levels were reduced by 70%."3.69Intracellular Localization and intercellular heterogeneity of the human DNA repair protein O(6)-methylguanine-DNA methyltransferase. ( Alas, LG; Belanich, M; Citron, ML; Dolan, ME; Gander, M; Kibitel, JT; Lejeune, FJ; Li, BF; Pastor, MA; Randall, T; Schold, SC; Wasserman, P; White, AB; Yarosh, DB, 1996)
"Patients with multiple brain metastases from NSCLC aged ≥ 18 years, classified according to recursive partitioning analysis class I or II and with adequate organ functions were eligible."2.78Temozolomide added to whole brain radiotherapy in patients with multiple brain metastases of non-small-cell lung cancer: a multicentric Austrian phase II study. ( Altorjai, G; Dieckmann, K; Geissler, K; Hassler, MR; Knocke-Abulesz, TH; Marosi, C; Pfeifer, W, 2013)
"NSCLC patients with 1 to 3 brain metastases were randomized to receive WBRT (2."2.78A phase 3 trial of whole brain radiation therapy and stereotactic radiosurgery alone versus WBRT and SRS with temozolomide or erlotinib for non-small cell lung cancer and 1 to 3 brain metastases: Radiation Therapy Oncology Group 0320. ( Buyyounouski, MK; Demas, W; Khuntia, D; Komaki, R; Mehta, MP; Nedzi, LA; Perry, G; Robins, HI; Schell, MC; Shah, SA; Souhami, L; Sperduto, PW; Suh, JH; Wang, M; Werner-Wasik, M, 2013)
"The LMD source was breast cancer (53 %) and non-small-cell lung cancer (37 %)."2.77Phase II trial of temozolomide for leptomeningeal metastases in patients with solid tumors. ( Balañá, C; Bruna, J; Chacón, I; Gil, M; Langa, JM; Martín, M; Segura, PP, 2012)
"Patients with brain metastases (BM) rarely survive longer than 6months and are commonly excluded from clinical trials."2.77Outcome, quality of life and cognitive function of patients with brain metastases from non-small cell lung cancer treated with whole brain radiotherapy combined with gefitinib or temozolomide. A randomised phase II trial of the Swiss Group for Clinical Ca ( Anchisi, S; Bernhard, J; Bodis, S; Caspar, CB; Cathomas, R; D'Addario, G; Fischer, N; Klingbiel, D; Kotrubczik, NM; Mayer, M; Pesce, GA; Peters, S; Pilop, C; Pless, M; Ribi, K; Schlaeppi, M; Stupp, R; von Moos, R; Weber, DC; Zouhair, A, 2012)
"Temozolomide has activity in relapsed SCLC, particularly for brain metastases."2.77Phase II trial of temozolomide in patients with relapsed sensitive or refractory small cell lung cancer, with assessment of methylguanine-DNA methyltransferase as a potential biomarker. ( Azzoli, CG; Chan, TA; Fiore, JJ; Ginsberg, MS; Heguy, A; Holodny, AI; Huberman, K; Kadota, K; Kris, MG; Krug, LM; Pietanza, MC; Riely, GJ; Rizvi, NA; Sima, CS; Sumner, DK; Travis, WD, 2012)
"Temozolomide was administered at a dose of 75 mg/m/day from days 2-6 and subsequent cohorts were dose escalated by 25 mg/m increments."2.76Phase I dose finding study of carboplatin, paclitaxel, and temozolomide in advanced solid tumors. ( Lee, FC; Mangalik, A; Movva, S; Parks, V; Rabinowitz, I; Verschraegen, CF, 2011)
"Temozolomide was administered at a dose of 75 mg/m(2) daily for 21 days every 28 days."2.74Continuous administration of daily low-dose temozolomide in pretreated patients with advanced non-small cell lung cancer: a phase II study. ( Georgoulias, V; Giassas, S; Kalbakis, K; Kalykaki, A; Kentepozidis, N; Kotsakis, A; Kouroussis, C; Saridaki, Z; Vamvakas, L; Vardakis, N, 2009)
"33 patients with brain metastases were included in the study and treated with TMZ 60 mg/m2/day (days 1-16) concomitantly with WBI (36 Gy/12 fractions given in 16 days)."2.73Phase II study of temozolomide and concomitant whole-brain radiotherapy in patients with brain metastases from solid tumors. ( Balafouta, MJ; Kolokouris, D; Kouloulias, VE; Kouvaris, JR; Miliadou, A; Papacharalampous, XN; Vlahos, LJ, 2007)
"Temozolomide (TMZ) has shown modest efficacy in the treatment of recurrent brain metastasis (BM)."2.72Vinorelbine combined with a protracted course of temozolomide for recurrent brain metastases: a phase I trial. ( Abrey, LE; Demopoulos, A; Malkin, MG; Omuro, AM; Raizer, JJ, 2006)
"Temozolomide is a rapidly absorbed chemotherapeutic agent, achieving significant central nervous system penetration."2.72Alternating chemo-immunotherapy with temozolomide and low-dose interleukin-2 in patients with metastatic melanoma. ( Hansson, J; Månsson-Brahme, E; Masucci, GV; Nilsson, B; Ragnarsson-Olding, B; Wagenius, G, 2006)
"Temozolomide was administered orally at 150 mg/mq/day for five consecutive days for the first cycle, doses were increased to 200 mg/mq/day for 5 days every 28 days for subsequent cycles if no grade 3/4 haematological toxicity was observed."2.71Oral temozolomide in heavily pre-treated brain metastases from non-small cell lung cancer: phase II study. ( Blanco, G; Bordonaro, R; Castorina, S; Failla, G; Giorgio, CG; Giuffrida, D; Pappalardo, A; Russo, A; Salice, P; Santini, D, 2005)
"Patients (n=32) with brain metastases were treated with TMZ 150 mg/m2/day (chemotherapy-pretreated) or 200 mg/m2/day (chemotherapy-naive) for 5 days, combined with CDDP 75 mg/m2 on day 1, every 28 days."2.71Temozolomide (TMZ) combined with cisplatin (CDDP) in patients with brain metastases from solid tumors: a Hellenic Cooperative Oncology Group (HeCOG) Phase II study. ( Aravantinos, G; Bafaloukos, D; Bamias, A; Carina, M; Christodoulou, C; Klouvas, G; Linardou, H; Skarlos, D, 2005)
"Everolimus is an appropriate first-line choice for somatostatin receptor negative tumors and for any patients with progressive disease."2.66Pulmonary Neuroendocrine Tumors: Adjuvant and Systemic Treatments. ( Halfdanarson, TR; Leventakos, K; Molina, JR; Uprety, D, 2020)
"The standard treatment for brain metastases is radiotherapy."2.55Combined treatment for non-small cell lung cancer and breast cancer patients with brain metastases with whole brain radiotherapy and temozolomide: a systematic review and meta-analysis. ( Luo, Y; Tang, J; Tian, J; Xiang, J, 2017)
"Pulmonary carcinoids (PCs) are rare tumors."2.52Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids. ( Baudin, E; Caplin, ME; Ferolla, P; Filosso, P; Garcia-Yuste, M; Lim, E; Oberg, K; Pelosi, G; Perren, A; Rossi, RE; Travis, WD, 2015)
"Later, TMZ proved its efficacy in the treatment of melanoma."2.49Temozolomide and unusual indications: review of literature. ( Abrial, C; Durando, X; Gadea, E; Gimbergues, P; Planchat, E; Tatar, Z; Thivat, E, 2013)
" Overall, we have verified that TMZ in addition to being an alkylating and cytotoxic chemotherapy, also possess immune modulatory effect in MM patients treated with standard dosage of TMZ."2.49Immune modulations during chemoimmunotherapy & novel vaccine strategies--in metastatic melanoma and non small-cell lung cancer. ( Iversen, TZ, 2013)
"As long as metastasis is confined to one organ system and is removable, surgery remains the treatment of first choice."2.42[Therapy of malignant melanoma at the stage of distant metastasis]. ( Eigentler, TK; Garbe, C, 2004)
" The efficacy was significantly improved after lobaplatin combined with pemetrexed, temozolomide and bevacizumab."1.56Chemotherapy combined with bevacizumab for the treatment of advanced lung adenocarcinoma cancer harboring EGFR-ANXA2, EGFR-RAD51, ATR and BRCA2 mutations: A case report. ( Cheng, Y; Huang, Z; Li, H; Liu, J; Liu, Y; Zhang, S; Zhong, R, 2020)
"We performed a retrospective analysis to compare the efficacy of whole brain radiotherapy (WBRT) combined with temozolomide (TMZ) versus WBRT alone as first-line treatment for brain metastases (BM)."1.48Effectiveness of temozolomide combined with whole brain radiotherapy for non-small cell lung cancer brain metastases. ( Fu, L; Guo, D; Jing, W; Kong, L; Yu, J; Zhu, Y, 2018)
"Temozolomide (TMZ) has been successfully used to treat a variety of malignancies, such as glioblastoma multiforme, astrocytoma, non-small-cell lung carcinoma."1.48Successful treatment with temozolomide in an elderly woman with advanced pulmonary large-cell neuroendocrine carcinoma: A case report. ( Dong, XF; Hu, ZL; Lu, YF; Tang, S; Wei, J, 2018)
" BBBD temozolomide was toxic in the efficacy study, but there was no evidence of symptomatic neurotoxicity in rats given IA temozolomide."1.43Intra-arterial administration improves temozolomide delivery and efficacy in a model of intracerebral metastasis, but has unexpected brain toxicity. ( Muldoon, LL; Netto, JP; Neuwelt, EA; Pagel, MA, 2016)
" We therefore evaluated a 5-day dosing schedule of temozolomide and examined MGMT as a predictive biomarker for temozolomide treatment in SCLC."1.40Trial of a 5-day dosing regimen of temozolomide in patients with relapsed small cell lung cancers with assessment of methylguanine-DNA methyltransferase. ( Bergagnini, I; Drilon, A; Ginsberg, MS; Heguy, A; Holodny, AI; Huberman, K; Kadota, K; Kris, MG; Krug, LM; Pietanza, MC; Riely, GJ; Sima, CS; Sumner, DK; Travis, WD; Zauderer, MG, 2014)
"WBRT followed by IMBRT combined with concomitant TMZ is well tolerated, yielding an encouraging objective response rate; however, overall survival improves slightly comparing with RTOG 9508 randomized trial."1.40Whole brain radiation therapy followed by intensity-modulated boosting treatment combined with concomitant temozolomide for brain metastases from non-small-cell lung cancer. ( Jiang, Z; Leng, C; Liang, S; Liu, H; Lu, F; Lu, S; Qi, X; Shi, J; Wang, Q; Wang, S, 2014)
"MGMT expression in brain metastases was significantly correlated with better survival."1.36O(6)-Methylguanine-DNA methyltransferase expression and prognostic value in brain metastases of lung cancers. ( Cheng, AL; Kuo, KT; Kuo, LT; Lee, WC; Lin, CH; Lin, YT; Lu, YS; Tasi, JC; Tseng, HM; Tseng, SH; Tu, YK; Wu, PF; Wu, RM; Yang, CH, 2010)
"Temozolomide was formulated as a suspension, which was elaborated and evaluated in terms of particle size, shape and agglomeration."1.36In vivo assessment of temozolomide local delivery for lung cancer inhalation therapy. ( Adanja, I; Amighi, K; Debeir, O; Decaestecker, C; Deleuze, P; Hecq, J; Kiss, R; Mathieu, V; Roland, I; Saussez, S; Wauthoz, N, 2010)
"First clinical reports on treating brain metastases with temozolomide describe varying effects."1.35Homogeneous MGMT immunoreactivity correlates with an unmethylated MGMT promoter status in brain metastases of various solid tumors. ( Heppner, FL; Ingold, B; Moch, H; Schraml, P, 2009)
"The patient remained free from disease progression for a total of 15 months when she was treated for dehydration and a computed tomography (CT) scan showed new small bilateral pleural effusions and enlarging subcarinal, right hilar, and left infrahilar lymph nodes."1.33Response to temozolomide in second-line treatment of recurrent nonsmall cell lung carcinoma: case report. ( Langer, CJ; Somer, RA, 2005)
" Temozolomide, an orally bioavailable alkylating agent that crosses the blood-brain barrier, has activity against brain metastases from both small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) when used as a single agent, but response rates are low."1.32Use of temozolomide with other cytotoxic chemotherapy in the treatment of patients with recurrent brain metastases from lung cancer. ( Ebert, BL; Niemierko, E; Salgia, R; Shaffer, K, 2003)
"Temozolomide was studied using a continuous exposure at final concentrations from 0."1.30Activity of temozolomide against human tumor colony-forming units. ( Dugan, M; Gerson, SL; Izbicka, E; Raymond, E; Soda, H; Von Hoff, DD, 1997)
"), and a bioavailability of 0."1.27Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine. ( Baig, G; Chubb, D; Gibson, NW; Goddard, C; Hickman, JA; Langdon, SP; Slack, JA; Stevens, MF; Stone, R; Vickers, L, 1987)

Research

Studies (109)

TimeframeStudies, this research(%)All Research%
pre-19902 (1.83)18.7374
1990's3 (2.75)18.2507
2000's35 (32.11)29.6817
2010's53 (48.62)24.3611
2020's16 (14.68)2.80

Authors

AuthorsStudies
Han, J1
Qiu, M1
Su, L1
Wu, C1
Cheng, S1
Zhao, Z2
Li, D3
Wang, M2
Tao, W1
Du, S1
Stanzione, M1
Zhong, J1
Wong, E1
LaSalle, TJ1
Wise, JF1
Simoneau, A1
Myers, DT1
Phat, S1
Sade-Feldman, M1
Lawrence, MS1
Hadden, MK1
Zou, L1
Farago, AF1
Dyson, NJ1
Drapkin, BJ1
Hiddinga, B1
Zwaenepoel, K1
Janssens, A2
Van Meerbeeck, J1
Pauwels, P2
Sun, F1
Grenert, JP1
Tan, L1
Van Ziffle, J1
Joseph, NM1
Mulvey, CK1
Bergsland, E1
Owen, DH2
Benner, B2
Wei, L2
Sukrithan, V1
Goyal, A1
Zhou, Y1
Pilcher, C2
Suffren, SA1
Christenson, G1
Curtis, N1
Jukich, M1
Schwarz, E1
Savardekar, H2
Norman, R2
Ferguson, S1
Kleiber, B1
Wesolowski, R2
Carson, WE2
Otterson, GA2
Verschraegen, CF3
Shah, MH1
Konda, B2
Ørting, AM1
Clausen, MM1
Soldath, P1
Petersen, RH1
Knigge, U1
Andreassen, M1
Kjær, A1
Langer, SW1
Papaxoinis, G1
Kordatou, Z1
McCallum, L1
Nasralla, M1
Lamarca, A1
Backen, A1
Nonaka, D1
Mansoor, W1
Pacheco, JM1
Byers, LA3
Zhong, R1
Li, H5
Liu, Y5
Zhang, S3
Liu, J1
Huang, Z2
Cheng, Y1
Duan, H1
Zheng, SY1
Zhou, T2
Cui, HJ1
Hu, KW1
Rathkey, D1
Khanal, M1
Murai, J2
Zhang, J4
Sengupta, M2
Jiang, Q1
Morrow, B1
Evans, CN1
Chari, R1
Fetsch, P1
Chung, HJ1
Xi, L1
Roth, M1
Filie, A1
Raffeld, M1
Thomas, A1
Pommier, Y2
Hassan, R2
Yang, H2
Xu, D1
Gao, Y3
Schmid, RA1
Peng, RW1
Uprety, D1
Halfdanarson, TR1
Molina, JR1
Leventakos, K1
Nguépy Keubo, FR1
Mboua, PC1
Djifack Tadongfack, T1
Fokouong Tchoffo, E1
Tasson Tatang, C1
Ide Zeuna, J1
Noupoue, EM1
Tsoplifack, CB1
Folefack, GO1
Kettani, M1
Bandelier, P1
Huo, J1
Yu, D1
Arulsamy, N1
AlAbbad, S1
Sardot, T1
Lekashvili, O1
Decato, D1
Lelj, F1
Alexander Ross, JB1
Rosenberg, E1
Nazir, H1
Muthuswamy, N1
Louis, C1
Jose, S1
Prakash, J1
Buan, MEM1
Flox, C1
Chavan, S1
Shi, X1
Kauranen, P1
Kallio, T1
Maia, G1
Tammeveski, K1
Lymperopoulos, N1
Carcadea, E1
Veziroglu, E1
Iranzo, A1
M Kannan, A1
Arunamata, A1
Tacy, TA1
Kache, S1
Mainwaring, RD1
Ma, M1
Maeda, K1
Punn, R1
Noguchi, S1
Hahn, S3
Iwasa, Y3
Ling, J2
Voccio, JP2
Kim, Y3
Song, J3
Bascuñán, J2
Chu, Y1
Tomita, M1
Cazorla, M1
Herrera, E1
Palomeque, E1
Saud, N1
Hoplock, LB1
Lobchuk, MM1
Lemoine, J1
Li, X10
Henson, MA1
Unsihuay, D1
Qiu, J1
Swaroop, S1
Nagornov, KO1
Kozhinov, AN1
Tsybin, YO1
Kuang, S1
Laskin, J1
Zin, NNINM1
Mohamad, MN1
Roslan, K1
Abdul Wafi, S1
Abdul Moin, NI1
Alias, A1
Zakaria, Y1
Abu-Bakar, N1
Naveed, A1
Jilani, K1
Siddique, AB1
Akbar, M1
Riaz, M1
Mushtaq, Z1
Sikandar, M1
Ilyas, S1
Bibi, I1
Asghar, A1
Rasool, G1
Irfan, M1
Li, XY1
Zhao, S1
Fan, XH1
Chen, KP1
Hua, W1
Liu, ZM1
Xue, XD1
Zhou, B1
Xing, YL1
Chen, MA1
Sun, Y1
Neradilek, MB1
Wu, XT1
Zhang, D2
Huang, W1
Cui, Y1
Yang, QQ1
Li, HW1
Zhao, XQ1
Hossein Rashidi, B1
Tarafdari, A1
Ghazimirsaeed, ST1
Shahrokh Tehraninezhad, E1
Keikha, F1
Eslami, B1
Ghazimirsaeed, SM1
Jafarabadi, M1
Silvani, Y1
Lovita, AND1
Maharani, A1
Wiyasa, IWA1
Sujuti, H1
Ratnawati, R1
Raras, TYM1
Lemin, AS1
Rahman, MM1
Pangarah, CA1
Kiyu, A1
Zeng, C2
Du, H1
Lin, D1
Jalan, D1
Rubagumya, F1
Hopman, WM1
Vanderpuye, V1
Lopes, G1
Seruga, B1
Booth, CM1
Berry, S1
Hammad, N1
Sajo, EA1
Okunade, KS1
Olorunfemi, G1
Rabiu, KA1
Anorlu, RI1
Xu, C2
Xiang, Y1
Xu, X1
Zhou, L2
Dong, X1
Tang, S2
Gao, XC1
Wei, CH1
Zhang, RG1
Cai, Q1
He, Y1
Tong, F1
Dong, JH1
Wu, G1
Dong, XR1
Tang, X1
Tao, F1
Xiang, W1
Zhao, Y2
Jin, L1
Tao, H1
Lei, Y1
Gan, H1
Huang, Y1
Chen, Y3
Chen, L3
Shan, A1
Zhao, H3
Wu, M2
Ma, Q1
Wang, J6
Zhang, E1
Li, Y5
Xue, F1
Deng, L1
Liu, L2
Yan, Z2
Wang, Y2
Meng, J1
Chen, G2
Anastassiadou, M1
Bernasconi, G1
Brancato, A1
Carrasco Cabrera, L1
Greco, L1
Jarrah, S1
Kazocina, A1
Leuschner, R1
Magrans, JO1
Miron, I1
Nave, S1
Pedersen, R1
Reich, H1
Rojas, A1
Sacchi, A1
Santos, M1
Theobald, A1
Vagenende, B1
Verani, A1
Du, L1
Liu, X1
Ren, Y1
Li, J9
Li, P1
Jiao, Q1
Meng, P1
Wang, F2
Wang, YS1
Wang, C3
Zhou, X2
Wang, W3
Wang, S3
Hou, J1
Zhang, A1
Lv, B1
Gao, C1
Pang, D1
Lu, K1
Ahmad, NH1
Wang, L1
Zhu, J2
Zhang, L2
Zhuang, T1
Tu, J1
Qu, Y1
Yao, H1
Wang, X8
Lee, DF1
Shen, J3
Wen, L1
Huang, G2
Xie, X1
Zhao, Q1
Hu, W1
Zhang, Y4
Wu, X1
Lu, J2
Li, M1
Li, W2
Wu, W1
Du, F1
Ji, H1
Yang, X2
Xu, Z1
Wan, L1
Wen, Q1
Cho, CH1
Zou, C1
Xiao, Z1
Liao, J1
Su, X1
Bi, Z1
Su, Q1
Huang, H1
Wei, Y2
Na, KJ1
Choi, H1
Oh, HR1
Kim, YH1
Lee, SB1
Jung, YJ1
Koh, J1
Park, S1
Lee, HJ1
Jeon, YK1
Chung, DH1
Paeng, JC1
Park, IK1
Kang, CH1
Cheon, GJ1
Kang, KW1
Lee, DS1
Kim, YT1
Pajuelo-Lozano, N1
Alcalá, S1
Sainz, B1
Perona, R1
Sanchez-Perez, I1
Logotheti, S1
Marquardt, S1
Gupta, SK1
Richter, C1
Edelhäuser, BAH1
Engelmann, D1
Brenmoehl, J1
Söhnchen, C1
Murr, N1
Alpers, M1
Singh, KP1
Wolkenhauer, O1
Heckl, D1
Spitschak, A1
Pützer, BM1
Liao, Y1
Cheng, J1
Kong, X1
Li, S1
Zhang, M4
Zhang, H1
Yang, T2
Dong, Y1
Xu, Y1
Yuan, Z1
Cao, J1
Zheng, Y1
Luo, Z1
Mei, Z1
Yao, Y1
Liu, Z2
Liang, C1
Song, Y1
Yu, K1
Zhu, C1
Qian, J1
Ge, J1
Hu, J2
Wang, H2
Mi, Y1
Kong, H1
Xi, D1
Yan, W1
Luo, X1
Ning, Q1
Chang, X2
Zhang, T2
Wang, Q3
Rathore, MG1
Reddy, K1
Chen, H2
Shin, SH1
Ma, WY1
Bode, AM1
Dong, Z1
Mu, W1
Liu, C3
Gao, F1
Qi, Y1
Lu, H1
Zhang, X4
Cai, X1
Ji, RY1
Hou, Y3
Tian, J3
Shi, Y1
Ying, S1
Tan, M1
Feng, G1
Kuang, Y1
Chen, D1
Wu, D3
Zhu, ZQ1
Tang, HX1
Shi, ZE1
Kang, J1
Liu, Q1
Qi, J2
Mu, J1
Cong, Z1
Chen, S2
Fu, D1
Li, Z2
Celestrin, CP1
Rocha, GZ1
Stein, AM1
Guadagnini, D1
Tadelle, RM1
Saad, MJA1
Oliveira, AG1
Bianconi, V1
Bronzo, P1
Banach, M1
Sahebkar, A1
Mannarino, MR1
Pirro, M1
Patsourakos, NG1
Kouvari, M1
Kotidis, A1
Kalantzi, KI1
Tsoumani, ME1
Anastasiadis, F1
Andronikos, P1
Aslanidou, T1
Efraimidis, P1
Georgiopoulos, A1
Gerakiou, K1
Grigoriadou-Skouta, E1
Grigoropoulos, P1
Hatzopoulos, D1
Kartalis, A1
Lyras, A1
Markatos, G1
Mikrogeorgiou, A1
Myroforou, I1
Orkopoulos, A1
Pavlidis, P1
Petras, C1
Riga, M1
Skouloudi, M1
Smyrnioudis, N1
Thomaidis, K1
Tsikouri, GE1
Tsikouris, EI1
Zisimos, K1
Vavoulis, P1
Vitali, MG1
Vitsas, G1
Vogiatzidis, C1
Chantanis, S1
Fousas, S1
Panagiotakos, DB1
Tselepis, AD1
Jungen, C1
Alken, FA1
Eickholt, C1
Scherschel, K1
Kuklik, P1
Klatt, N1
Schwarzl, J1
Moser, J1
Jularic, M1
Akbulak, RO1
Schaeffer, B1
Willems, S1
Meyer, C1
Nowak, JK1
Szczepanik, M1
Trypuć, M1
Pogorzelski, A1
Bobkowski, W1
Grytczuk, M1
Minarowska, A1
Wójciak, R1
Walkowiak, J1
Lu, Y1
Xi, J1
Li, C1
Chen, W2
Hu, X1
Zhang, F1
Wei, H1
Wang, Z1
Gurzu, S1
Jung, I1
Sugimura, H2
Stefan-van Staden, RI1
Yamada, H1
Natsume, H1
Iwashita, Y1
Szodorai, R1
Szederjesi, J1
Yari, D1
Ehsanbakhsh, Z1
Validad, MH1
Langroudi, FH1
Esfandiari, H1
Prager, A1
Hassanpour, K1
Kurup, SP1
Mets-Halgrimson, R1
Yoon, H1
Zeid, JL1
Mets, MB1
Rahmani, B1
Araujo-Castillo, RV1
Culquichicón, C1
Solis Condor, R1
Efendi, F1
Sebayang, SK1
Astutik, E1
Hadisuyatmana, S1
Has, EMM1
Kuswanto, H1
Foroutan, T1
Ahmadi, F1
Moayer, F1
Khalvati, S1
Zhang, Q2
Lyu, Y1
Huang, J1
Yu, N1
Wen, Z1
Hou, H1
Zhao, T1
Gupta, A1
Khosla, N1
Govindasamy, V1
Saini, A1
Annapurna, K1
Dhakate, SR1
Akkaya, Ö1
Chandgude, AL1
Dömling, A1
Harnett, J1
Oakes, K1
Carè, J1
Leach, M1
Brown, D1
Cramer, H1
Pinder, TA1
Steel, A1
Anheyer, D1
Cantu, J1
Valle, J1
Flores, K1
Gonzalez, D1
Valdes, C1
Lopez, J1
Padilla, V1
Alcoutlabi, M1
Parsons, J1
Núñez, K1
Hamed, M1
Fort, D1
Bruce, D1
Thevenot, P1
Cohen, A1
Weber, P1
Menezes, AMB1
Gonçalves, H1
Perez-Padilla, R1
Jarvis, D1
de Oliveira, PD1
Wehrmeister, FC1
Mir, S1
Wong, J1
Ryan, CM1
Bellingham, G1
Singh, M2
Waseem, R1
Eckert, DJ1
Chung, F1
Hegde, H1
Shimpi, N1
Panny, A1
Glurich, I1
Christie, P1
Acharya, A1
English, KL1
Downs, M1
Goetchius, E1
Buxton, R1
Ryder, JW1
Ploutz-Snyder, R1
Guilliams, M1
Scott, JM1
Ploutz-Snyder, LL1
Martens, C1
Goplen, FK1
Aasen, T1
Gjestad, R1
Nordfalk, KF1
Nordahl, SHG1
Inoue, T1
Soshi, S1
Kubota, M1
Marumo, K1
Mortensen, NP1
Caffaro, MM1
Patel, PR2
Uddin, MJ1
Aravamudhan, S1
Sumner, SJ1
Fennell, TR1
Gal, RL1
Cohen, NJ1
Kruger, D1
Beck, RW1
Bergenstal, RM1
Calhoun, P1
Cushman, T1
Haban, A1
Hood, K1
Johnson, ML1
McArthur, T1
Olson, BA1
Weinstock, RS1
Oser, SM1
Oser, TK1
Bugielski, B1
Strayer, H1
Aleppo, G1
Maruyama, H1
Hirayama, K1
Yamashita, M1
Ohgi, K1
Tsujimoto, R1
Takayasu, M1
Shimohata, H1
Kobayashi, M1
Buscagan, TM1
Rees, DC1
Jaborek, JR1
Zerby, HN1
Wick, MP1
Fluharty, FL1
Moeller, SJ1
Razavi, P1
Dickler, MN1
Shah, PD1
Toy, W1
Brown, DN1
Won, HH1
Li, BT1
Shen, R1
Vasan, N1
Modi, S1
Jhaveri, K1
Caravella, BA1
Patil, S1
Selenica, P1
Zamora, S1
Cowan, AM1
Comen, E1
Singh, A1
Covey, A1
Berger, MF1
Hudis, CA1
Norton, L1
Nagy, RJ1
Odegaard, JI1
Lanman, RB1
Solit, DB1
Robson, ME1
Lacouture, ME1
Brogi, E1
Reis-Filho, JS1
Moynahan, ME1
Scaltriti, M1
Chandarlapaty, S1
Papouskova, K1
Moravcova, M1
Masrati, G1
Ben-Tal, N1
Sychrova, H1
Zimmermannova, O1
Fang, J1
Fan, Y1
Luo, T2
Su, H2
Tsetseris, L1
Anthopoulos, TD1
Liu, SF1
Zhao, K1
Sacan, O1
Turkyilmaz, IB1
Bayrak, BB1
Mutlu, O1
Akev, N1
Yanardag, R1
Gruber, S1
Kamnoedboon, P1
Özcan, M1
Srinivasan, M1
Jo, YH1
Oh, HK1
Jeong, SY1
Lee, BG1
Zheng, J1
Guan, H1
Tan, H1
Maji, TK1
J R, A1
Mukherjee, S1
Alexander, R1
Mondal, A1
Das, S1
Sharma, RK1
Chakraborty, NK1
Dasgupta, K1
Sharma, AMR1
Hawaldar, R1
Pandey, M1
Naik, A1
Majumdar, K1
Pal, SK1
Adarsh, KV1
Ray, SK1
Karmakar, D1
Ma, Y2
Gao, W1
Ma, S1
Lin, W1
Wu, T1
Wu, Q1
Ye, C1
He, X1
Jiang, F1
Yuan, D1
Chen, Q1
Hong, M1
Chen, K1
Hussain, M1
Razi, SS1
Yildiz, EA1
Zhao, J1
Yaglioglu, HG1
Donato, MD1
Jiang, J1
Jamil, MI1
Zhan, X1
Chen, F1
Cheng, D1
Wu, CT1
Utsunomiya, T1
Ichii, T1
Fujinami, S1
Nakajima, K1
Sanchez, DM1
Raucci, U1
Ferreras, KN1
Martínez, TJ1
Mordi, NA1
Mordi, IR1
Singh, JS1
McCrimmon, RJ1
Struthers, AD1
Lang, CC1
Wang, XW1
Yuan, LJ1
Yang, Y2
Chen, WF1
Luo, R1
Yang, K1
Amarasiri, SS1
Attanayake, AP1
Arawwawala, LDAM1
Jayatilaka, KAPW1
Mudduwa, LKB1
Ogunsuyi, O2
Akanni, O1
Alabi, O1
Alimba, C1
Adaramoye, O1
Cambier, S1
Eswara, S1
Gutleb, AC1
Bakare, A1
Gu, Z1
Cong, J1
Pellegrini, M1
Palmieri, S1
Ricci, A1
Serio, A1
Paparella, A1
Lo Sterzo, C1
Jadeja, SD1
Vaishnav, J1
Mansuri, MS1
Shah, C1
Mayatra, JM1
Shah, A1
Begum, R1
Song, H2
Lian, Y1
Wan, T1
Schultz-Lebahn, A1
Skipper, MT1
Hvas, AM1
Larsen, OH1
Hijazi, Z1
Granger, CB1
Hohnloser, SH1
Westerbergh, J1
Lindbäck, J1
Alexander, JH1
Keltai, M1
Parkhomenko, A1
López-Sendón, JL1
Lopes, RD1
Siegbahn, A1
Wallentin, L1
El-Tarabany, MS1
Saleh, AA1
El-Araby, IE1
El-Magd, MA1
van Ginkel, MPH1
Schijven, MP1
van Grevenstein, WMU1
Schreuder, HWR1
Pereira, EDM1
da Silva, J1
Carvalho, PDS1
Grivicich, I1
Picada, JN1
Salgado Júnior, IB1
Vasques, GJ1
Pereira, MADS1
Reginatto, FH1
Ferraz, ABF1
Vasilenko, EA1
Gorshkova, EN1
Astrakhantseva, IV1
Drutskaya, MS1
Tillib, SV1
Nedospasov, SA1
Mokhonov, VV1
Nam, YW1
Cui, M1
Orfali, R1
Viegas, A1
Nguyen, M1
Mohammed, EHM1
Zoghebi, KA1
Rahighi, S1
Parang, K1
Patterson, KC1
Kahanovitch, U1
Gonçalves, CM1
Hablitz, JJ1
Staruschenko, A1
Mulkey, DK1
Olsen, ML1
Gu, L1
Cao, X1
Mukhtar, A1
Wu, K1
Zhang, YY1
Zhu, Y2
Lu, DZ1
Dong, W1
Bi, WJ1
Feng, XJ1
Wen, LM1
Sun, H1
Qi, MC1
Chang, CC1
Dinh, TK1
Lee, YA1
Wang, FN1
Sung, YC1
Yu, PL1
Chiu, SC1
Shih, YC1
Wu, CY1
Huang, YD1
Lu, TT1
Wan, D1
Sakizadeh, J1
Cline, JP1
Snyder, MA1
Kiely, CJ1
McIntosh, S1
Jiang, X1
Cao, JW1
Zhao, CK1
Yang, R1
Zhang, QY1
Chen, KJ2
Liu, H2
He, Z1
Chen, B1
Wu, J1
Du, X1
Moore, J1
Blank, BR1
Eksterowicz, J1
Sutimantanapi, D1
Yuen, N1
Metzger, T1
Chan, B1
Huang, T1
Chen, X1
Duong, F1
Kong, W1
Chang, JH1
Sun, J1
Zavorotinskaya, T1
Ye, Q1
Junttila, MR1
Ndubaku, C1
Friedman, LS1
Fantin, VR1
Sun, D1
Fei, P1
Xie, Q1
Jiang, Y1
Feng, H1
Chang, Y1
Kang, H1
Xing, M1
Chen, J1
Shao, Z1
Yuan, C1
Wu, Y1
Allan, R1
Canham, K1
Wallace, R1
Singh, D1
Ward, J1
Cooper, A1
Newcomb, C1
Nammour, S1
El Mobadder, M1
Maalouf, E1
Namour, M1
Namour, A1
Rey, G1
Matamba, P1
Matys, J1
Zeinoun, T1
Grzech-Leśniak, K1
Segabinazi Peserico, C1
Garozi, L1
Zagatto, AM1
Machado, FA1
Hirth, JM1
Dinehart, EE1
Lin, YL1
Kuo, YF1
Nouri, SS1
Ritchie, C1
Volow, A1
Li, B2
McSpadden, S1
Dearman, K1
Kotwal, A1
Sudore, RL1
Ward, L1
Thakur, A1
Kondadasula, SV1
Ji, K1
Schalk, DL1
Bliemeister, E1
Ung, J1
Aboukameel, A1
Casarez, E1
Sloane, BF1
Lum, LG1
Xiao, M1
Feng, X1
Gao, R1
Du, B1
Brooks, T1
Zwirner, J1
Hammer, N1
Ondruschka, B1
Jermy, M1
Luengo, A1
Marzo, I1
Reback, M1
Daubit, IM1
Fernández-Moreira, V1
Metzler-Nolte, N1
Gimeno, MC1
Tonchev, I1
Heberman, D1
Peretz, A1
Medvedovsky, AT1
Gotsman, I1
Rashi, Y1
Poles, L1
Goland, S1
Perlman, GY1
Danenberg, HD1
Beeri, R1
Shuvy, M1
Fu, Q1
Yang, D1
Sarapulova, A1
Pang, Q1
Meng, Y1
Ehrenberg, H1
Kim, CC1
Jeong, SH1
Oh, KH1
Nam, KT1
Sun, JY1
Ning, J1
Duan, Z1
Kershaw, SV1
Rogach, AL1
Gao, Z1
Wang, T1
Li, Q1
Cao, T1
Guo, L1
Fu, Y1
Seeger, ZL1
Izgorodina, EI1
Hue, S1
Beldi-Ferchiou, A1
Bendib, I1
Surenaud, M1
Fourati, S1
Frapard, T1
Rivoal, S1
Razazi, K1
Carteaux, G1
Delfau-Larue, MH1
Mekontso-Dessap, A1
Audureau, E1
de Prost, N1
Gao, SS1
Duangthip, D1
Lo, ECM1
Chu, CH1
Roberts, W1
Rosenheck, RA1
Miyake, T1
Kimoto, E1
Luo, L1
Mathialagan, S1
Horlbogen, LM1
Ramanathan, R1
Wood, LS1
Johnson, JG1
Le, VH1
Vourvahis, M1
Rodrigues, AD1
Muto, C1
Furihata, K1
Sugiyama, Y1
Kusuhara, H1
Gong, Q1
Song, W1
Sun, B1
Cao, P1
Gu, S1
Sun, X1
Zhou, G1
Toma, C1
Khandhar, S1
Zalewski, AM1
D'Auria, SJ1
Tu, TM1
Jaber, WA1
Cho, J2
Suwandaratne, NS1
Razek, S1
Choi, YH1
Piper, LFJ1
Watson, DF1
Banerjee, S1
Xie, S1
Lindsay, AP1
Bates, FS1
Lodge, TP1
Hao, Y1
Chapovetsky, A1
Liu, JJ1
Welborn, M1
Luna, JM1
Do, T1
Haiges, R1
Miller Iii, TF1
Marinescu, SC1
Lopez, SA1
Compter, I1
Eekers, DBP1
Hoeben, A1
Rouschop, KMA1
Reymen, B1
Ackermans, L1
Beckervordersantforth, J1
Bauer, NJC1
Anten, MM1
Wesseling, P1
Postma, AA1
De Ruysscher, D1
Lambin, P1
Qiang, L1
Yang, S1
Cui, YH1
He, YY1
Kumar, SK1
Jacobus, SJ1
Cohen, AD1
Weiss, M1
Callander, N1
Singh, AK1
Parker, TL1
Menter, A1
Parsons, B1
Kumar, P1
Kapoor, P1
Rosenberg, A1
Zonder, JA1
Faber, E1
Lonial, S1
Anderson, KC1
Richardson, PG1
Orlowski, RZ1
Wagner, LI1
Rajkumar, SV1
Li, G1
Hou, G1
Cui, J1
Xie, H1
Sun, Z1
Fang, Z1
Dunstand-Guzmán, E1
Hallal-Calleros, C1
Hernández-Velázquez, VM1
Canales-Vargas, EJ1
Domínguez-Roldan, R1
Pedernera, M1
Peña-Chora, G1
Flores-Pérez, I1
Kim, MJ1
Han, C1
White, K1
Park, HJ1
Ding, D1
Boyd, K1
Rothenberger, C1
Bose, U1
Carmichael, P1
Linser, PJ1
Tanokura, M1
Salvi, R1
Someya, S1
Samuni, A1
Goldstein, S1
Divya, KP1
Dharuman, V1
Feng, J2
Qian, Y1
Cheng, Q1
Ma, H1
Ren, X1
Wei, Q1
Pan, W1
Guo, J1
Situ, B1
An, T1
Zheng, L1
Augusto, S1
Ratola, N1
Tarín-Carrasco, P1
Jiménez-Guerrero, P1
Turco, M1
Schuhmacher, M1
Costa, S1
Teixeira, JP1
Costa, C1
Syed, A1
Marraiki, N1
Al-Rashed, S1
Elgorban, AM1
Yassin, MT1
Chankhanittha, T1
Nanan, S1
Sorokina, KN1
Samoylova, YV1
Gromov, NV1
Ogorodnikova, OL1
Parmon, VN1
Ye, J1
Liao, W1
Zhang, P2
Nabi, M1
Cai, Y1
Li, F1
Alsbou, EM1
Omari, KW1
Adeosun, WA1
Asiri, AM1
Marwani, HM1
Barral, M1
Jemal-Turki, A1
Beuvon, F1
Soyer, P1
Camparo, P1
Cornud, F1
Atwater, BD1
Jones, WS1
Loring, Z1
Friedman, DJ1
Namburath, M1
Papirio, S1
Moscariello, C1
Di Costanzo, N1
Pirozzi, F1
Alappat, BJ1
Sreekrishnan, TR1
Volpin, F1
Woo, YC1
Kim, H1
Freguia, S1
Jeong, N1
Choi, JS1
Phuntsho, S1
Shon, HK1
Domínguez-Zambrano, E1
Pedraza-Chaverri, J1
López-Santos, AL1
Medina-Campos, ON1
Cruz-Rivera, C1
Bueno-Hernández, F1
Espinosa-Cuevas, A1
Bulavaitė, A1
Dalgediene, I1
Michailoviene, V1
Pleckaityte, M1
Sauerbier, P1
Köhler, R1
Renner, G1
Militz, H1
Good, L1
Ghattas, C1
Shah, M1
Behbehani, GK1
Pu, Y1
Dai, N1
Wang, D1
Xu, M1
Luo, Y1
Xiang, J1
Tang, J1
Campana, D1
Walter, T2
Pusceddu, S1
Gelsomino, F1
Graillot, E1
Prinzi, N1
Spallanzani, A1
Fiorentino, M1
Barritault, M2
Dall'Olio, F1
Brighi, N1
Biasco, G2
Song, X6
Xie, L3
Chang, M2
Geng, X2
Chen, TC3
Xin, Y1
Guo, W1
Yang, CS1
Huang, Q1
Zhang, LZ1
Jiang, G1
Pietanza, MC5
Waqar, SN1
Krug, LM4
Dowlati, A1
Hann, CL1
Chiappori, A1
Owonikoko, TK2
Woo, KM1
Cardnell, RJ1
Fujimoto, J1
Long, L1
Diao, L2
Bensman, Y1
Hurtado, B1
de Groot, P1
Sulman, EP1
Wistuba, II1
Chen, A1
Fleisher, M1
Heymach, JV1
Kris, MG3
Rudin, CM2
Fu, L1
Jing, W1
Guo, D1
Kong, L1
Yu, J1
Sidaway, P1
Pujol, JL1
Roch, B1
Pujol, CN1
Goze, C1
Liang, F1
Nazha, B1
Wei, J1
Dong, XF1
Hu, ZL1
Lu, YF1
Schwartz, S1
Szeto, C1
Tian, Y1
Cecchi, F1
Corallo, S1
Calegari, MA1
Di Bartolomeo, M1
Morano, F1
Raimondi, A1
Fucà, G1
Martinetti, A1
De Pascalis, I1
Martini, M1
Belfiore, A1
Milione, M1
Orlandi, A1
Barault, L1
Barone, C1
de Braud, F1
Di Nicolantonio, F1
Benz, S1
Hembrough, T1
Pietrantonio, F1
Lemelin, A1
Hervieu, V1
Payen, L1
Péron, J1
Couvelard, A1
Cros, J1
Scoazec, JY1
Bin, S1
Villeneuve, L1
Lombard-Bohas, C1
Blume, C1
von Lehe, M1
van Landeghem, F1
Greschus, S1
Boström, J1
Hassler, MR1
Pfeifer, W1
Knocke-Abulesz, TH1
Geissler, K1
Altorjai, G1
Dieckmann, K1
Marosi, C1
Bazan, F1
Vollmer, I1
Gayete, A1
Polley, MY1
Freidlin, B1
Korn, EL1
Conley, BA1
Abrams, JS1
McShane, LM1
Iversen, TZ2
Lipson, EJ1
Bodell, MA1
Kraus, ES1
Sharfman, WH1
Leccia, MT1
Planchamp, F1
Sassolas, B1
Combemale, P1
Modiano, P1
Bedane, C1
Cupissol, D1
Derrey, S1
Dygai-Cochet, I1
Lamant, L1
Lubrano, V1
Mirabel, X1
Mourrégot, A1
Rougé Bugat, ME1
Siegrist, S1
Thariat, J1
Tiffet, O1
Truc, G1
Verdoni, L1
Mazeau-Woynar, V1
Minniti, G1
Scaringi, C1
Lanzetta, G1
Bozzao, A1
Romano, A1
De Sanctis, V1
Valeriani, M1
Osti, M1
Enrici, RM1
Jiang, Z1
Qi, X1
Lu, S1
Leng, C1
Lu, F1
Liang, S1
Shi, J1
Boggs, DH1
Robins, HI3
Langer, CJ2
Traynor, AM2
Berkowitz, MJ1
Mehta, MP2
Zauderer, MG1
Drilon, A1
Kadota, K2
Huberman, K2
Sima, CS2
Bergagnini, I1
Sumner, DK2
Travis, WD3
Heguy, A2
Ginsberg, MS2
Holodny, AI2
Riely, GJ2
Andersen, MH1
Svane, IM1
Caplin, ME1
Baudin, E1
Ferolla, P1
Filosso, P1
Garcia-Yuste, M1
Lim, E1
Oberg, K1
Pelosi, G1
Perren, A1
Rossi, RE1
Rosière, R1
Gelbcke, M1
Mathieu, V2
Van Antwerpen, P1
Amighi, K3
Wauthoz, N3
Gomez-Gutierrez, JG1
Nitz, J1
Sharma, R1
Wechman, SL1
Riedinger, E1
Martinez-Jaramillo, E1
Sam Zhou, H1
McMasters, KM1
Muldoon, LL1
Pagel, MA1
Netto, JP1
Neuwelt, EA1
Zeng, Q1
Papadodima, O1
Moulos, P1
Koryllou, A1
Piroti, G1
Kolisis, F1
Chatziioannou, A1
Pletsa, V1
Hiddinga, BI1
van Meerbeeck, JP1
Deng, X1
Zheng, Z1
Lin, B1
Fei, S1
Fei, Z1
Zhao, L1
Jin, X1
Xie, CY1
Hamzawy, MA1
Abo-Youssef, AM1
Salem, HF1
Mohammed, SA1
Addeo, R1
De Rosa, C1
Faiola, V1
Leo, L1
Cennamo, G1
Montella, L1
Guarrasi, R1
Vincenzi, B1
Caraglia, M1
Del Prete, S2
Kouroussis, C1
Vamvakas, L1
Vardakis, N1
Kotsakis, A1
Kalykaki, A1
Kalbakis, K1
Saridaki, Z1
Kentepozidis, N1
Giassas, S1
Georgoulias, V1
Ingold, B1
Schraml, P1
Heppner, FL1
Moch, H1
Adema, AD1
van der Born, K1
Honeywell, RJ1
Peters, GJ1
Nikolova, T1
Christmann, M1
Kaina, B1
Wu, PF1
Kuo, KT1
Kuo, LT1
Lin, YT1
Lee, WC1
Lu, YS1
Yang, CH1
Wu, RM1
Tu, YK1
Tasi, JC1
Tseng, HM1
Tseng, SH1
Cheng, AL1
Lin, CH1
Siena, S1
Crinò, L1
Danova, M1
Cascinu, S1
Salvagni, S1
Schiavetto, I1
Vitali, M1
Bajetta, E1
Bocangel, D1
Sengupta, S1
Mitra, S1
Bhakat, KK1
Deleuze, P2
Hecq, J1
Roland, I1
Saussez, S1
Adanja, I1
Debeir, O1
Decaestecker, C1
Kiss, R2
Chua, D1
Krzakowski, M1
Chouaid, C1
Pallotta, MG1
Martinez, JI1
Gottfried, M1
Curran, W1
Throuvalas, N1
Zauderer, M1
O'Rourke, D1
Pregun, I1
Bodoky, G1
Rácz, K1
Tulassay, Z1
Saumet, A1
Duret, C1
Movva, S1
Rabinowitz, I1
Mangalik, A1
Parks, V1
Lee, FC1
Leng, S1
Bernauer, AM1
Hong, C1
Do, KC1
Yingling, CM1
Flores, KG1
Tessema, M1
Tellez, CS1
Willink, RP1
Burki, EA1
Picchi, MA1
Stidley, CA1
Prados, MD1
Costello, JF1
Gilliland, FD1
Crowell, RE1
Belinsky, SA1
Pesce, GA1
Klingbiel, D1
Ribi, K1
Zouhair, A1
von Moos, R1
Schlaeppi, M1
Caspar, CB1
Fischer, N1
Anchisi, S1
Peters, S1
Cathomas, R1
Bernhard, J1
Kotrubczik, NM1
D'Addario, G1
Pilop, C1
Weber, DC1
Bodis, S1
Pless, M1
Mayer, M1
Stupp, R1
Fiore, JJ1
Chan, TA1
Rizvi, NA1
Azzoli, CG1
Liu, ZF1
Li, HQ1
Tao, RJ1
Segura, PP1
Gil, M1
Balañá, C1
Chacón, I1
Langa, JM1
Martín, M1
Bruna, J1
Tatar, Z1
Thivat, E1
Planchat, E1
Gimbergues, P1
Gadea, E1
Abrial, C1
Durando, X1
Mayes, PA1
Degenhardt, YY1
Wood, A1
Toporovskya, Y1
Diskin, SJ1
Haglund, E1
Moy, C1
Wooster, R1
Maris, JM1
Sperduto, PW1
Schell, MC1
Werner-Wasik, M1
Komaki, R1
Souhami, L1
Buyyounouski, MK1
Khuntia, D1
Demas, W1
Shah, SA1
Nedzi, LA1
Perry, G1
Suh, JH1
Ebert, BL1
Niemierko, E1
Shaffer, K1
Salgia, R1
Miknyoczki, SJ1
Jones-Bolin, S1
Pritchard, S1
Hunter, K1
Wan, W1
Ator, M1
Bihovsky, R1
Hudkins, R1
Chatterjee, S1
Klein-Szanto, A1
Dionne, C1
Ruggeri, B1
Dziadziuszko, R1
Ardizzoni, A1
Postmus, PE1
Smit, EF1
Price, A1
Debruyne, C1
Legrand, C1
Giaccone, G1
Calabrese, CR1
Almassy, R1
Barton, S1
Batey, MA1
Calvert, AH3
Canan-Koch, S1
Durkacz, BW2
Hostomsky, Z3
Kumpf, RA1
Kyle, S3
Maegley, K1
Newell, DR2
Notarianni, E1
Stratford, IJ1
Skalitzky, D1
Thomas, HD1
Wang, LZ2
Webber, SE2
Williams, KJ1
Curtin, NJ3
Garbe, C1
Eigentler, TK1
White, AW2
Eastman, BW1
Golding, BT1
Maegley, KA1
Skalitzky, DJ1
Yu, XH1
Griffin, RJ1
Richtig, E1
Hofmann-Wellenhof, R1
Pehamberger, H1
Forstinger, Ch1
Wolff, K1
Mischer, P1
Raml, J1
Fritsch, P1
Zelger, B1
Ratzinger, G1
Koller, J1
Lang, A1
Konrad, K1
Kindermann-Glebowski, E1
Seeber, A1
Steiner, A1
Fialla, R1
Pachinger, W1
Kos, C1
Klein, G1
Kehrer, H1
Kerl, H1
Ulmer, H1
Smolle, J1
Christodoulou, C2
Bafaloukos, D1
Linardou, H1
Aravantinos, G1
Bamias, A1
Carina, M1
Klouvas, G1
Skarlos, D1
Somer, RA1
Giorgio, CG1
Giuffrida, D1
Pappalardo, A1
Russo, A1
Santini, D1
Salice, P1
Blanco, G1
Castorina, S1
Failla, G1
Bordonaro, R1
Garcia del Muro, X1
Lopez-Pousa, A1
Martin, J1
Buesa, JM1
Martinez-Trufero, J1
Casado, A1
Poveda, A1
Cruz, J1
Bover, I1
Maurel, J1
Narita, Y1
Kundranda, MN1
Clark, CT1
Chaudhry, AA1
Chan, V1
Daw, HA1
Omuro, AM1
Raizer, JJ2
Demopoulos, A1
Malkin, MG2
Abrey, LE3
Moreno Antón, F1
Casado Herraez, A1
Puente Vázquez, J1
Gómez Díaz, R1
Aragoncillo, P1
Díaz-Rubio García, E1
Cortot, AB1
Gerinière, L1
Robinet, G1
Breton, JL1
Corre, R1
Falchero, L1
Berard, H1
Gimenez, C1
Chavaillon, JM1
Perol, M1
Bombaron, P1
Mercier, C1
Souquet, PJ1
Masucci, GV1
Månsson-Brahme, E1
Ragnarsson-Olding, B1
Nilsson, B1
Wagenius, G1
Hansson, J1
Choong, NW1
Mauer, AM1
Hoffman, PC1
Winegarden, JD1
Villano, JL1
Kozloff, M1
Wade, JL1
Sciortino, DF1
Szeto, L1
Vokes, EE1
Mehta, M1
Weller, M1
Kouvaris, JR1
Miliadou, A1
Kouloulias, VE1
Kolokouris, D1
Balafouta, MJ1
Papacharalampous, XN1
Vlahos, LJ1
Sawrie, SM1
Guthrie, BL1
Spencer, SA1
Nordal, RA1
Meredith, RF1
Markert, JM1
Cloud, GA1
Fiveash, JB1
Gounaris, I1
Rahamim, J1
Shivasankar, S1
Earl, S1
Lyons, B1
Yiannakis, D1
Dehart, WK1
Gilliam, AC1
Lu, KQ1
Brell, J1
Belanich, M1
Randall, T1
Pastor, MA1
Kibitel, JT1
Alas, LG1
Dolan, ME1
Schold, SC1
Gander, M1
Lejeune, FJ1
Li, BF1
White, AB1
Wasserman, P1
Citron, ML1
Yarosh, DB1
Raymond, E1
Izbicka, E1
Soda, H1
Gerson, SL1
Dugan, M1
Von Hoff, DD1
Delaney, CA1
Pantaleo, MA1
Casadei, S1
Olson, JD1
Mack, M1
Rodavitch, A1
Boutros, DY1
Paul, MJ1
Summers, Y1
Rustin, G1
Brampton, MH1
Thatcher, N1
Middleton, MR1
Deans, B1
Tisdale, MJ2
Stevens, MF1
Hickman, JA1
Langdon, SP1
Chubb, D1
Vickers, L1
Stone, R1
Baig, G1
Goddard, C1
Gibson, NW1
Slack, JA1

Clinical Trials (17)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A First-line Multi-center, Single-arm Exploratory Study Using Low-dose Radiotherapy (LDRT) Combined With Durvalumab (MEDI4736), Etoposide, and Cisplatin/Carboplatin for Patients With Extensive-stage Small Cell Lung Cancer[NCT05092412]Phase 230 participants (Anticipated)Interventional2022-03-02Recruiting
A Phase II, Multi-Cohort Trial of Combination Nivolumab and Temozolomide in Recurrent/Refractory Small-Cell Lung Cancer and Advanced Neuroendocrine Tumors[NCT03728361]Phase 255 participants (Actual)Interventional2018-12-31Active, not recruiting
Nitroglycerin Plus Whole Intracranial Radiotherapy for Brain Metastases in Non-small Cell Lung Cancer Patients: a Phase II Open Randomized Clinical Trial[NCT04338867]Phase 296 participants (Actual)Interventional2020-03-01Completed
A Multi-Center, Randomized, Double-Blind Phase II Study Comparing ABT-888, a PARP Inhibitor, Versus Placebo With Temozolomide in Patients With Relapsed Sensitive or Refractory Small Cell Lung Cancer[NCT01638546]Phase 297 participants (Actual)Interventional2012-06-30Completed
Multicenter Phase II Study of Preoperative Chemoradiotherapy With CApecitabine Plus Temozolomide in Patients With MGMT Silenced and Microsatellite Stable Locally Advanced RecTal Cancer: the CATARTIC Trial[NCT05136326]Phase 221 participants (Anticipated)Interventional2021-12-01Recruiting
Temozolomide and Irinotecan Consolidation in Patients With MGMT Silenced, Microsatellite Stable Colorectal Cancer With Persistence of Minimal Residual Disease in Liquid Biopsy After Standard Adjuvant Chemotherapy: the ERASE-TMZ Study[NCT05031975]Phase 235 participants (Anticipated)Interventional2022-05-02Recruiting
MGMT-NET: O6-methylguanine-DNA Methyltransferase (MGMT) Status in Neuroendocrine Tumors: Predictive Factor of Response to Alkylating Agents[NCT03217097]116 participants (Actual)Interventional2018-10-16Completed
A Randomized Phase 2 Study of Maintenance Temozolomide Versus Observation in Stable or Responding Stage III/IV Non-Small Cell Lung Cancer Patients[NCT00632203]Phase 253 participants (Actual)Interventional2008-03-04Terminated
Overall Survival and Progression Free Survival of Patients With Large Cell Neuroendocrine Lung Cancer and Combined Large Cell Neuroendocrine Lung Cancer Treated in Clinical Stage I-IV[NCT03998332]132 participants (Actual)Observational2002-01-01Completed
Multicenter Phase 2 Evaluation of Temozolomide for Treatment of Brain Metastases of Either Malignant Melanoma, Breast and Non-small Cell Lung Cancer.[NCT00831545]Phase 2162 participants (Actual)Interventional2000-12-01Completed
A Randomized, Open-Label Phase 2 Study of Temozolomide Added to Whole Brain Radiation Therapy Versus Whole Brain Radiation Therapy Alone for the Treatment of Brain Metastasis From Non-Small Cell Lung Cancer[NCT00076856]Phase 295 participants (Actual)Interventional2004-03-31Completed
Whole Brain Radiotherapy in Combination With Gefitinib (Iressa) or Temozolomide (Temodal) for Brain Metastases From Non-Small Lung Cancer (NSCLC) A Randomized Phase II Trial[NCT00238251]Phase 259 participants (Actual)Interventional2005-05-31Completed
IMRT Combined With Erlotinib Compared With Whole-brain Radiotherapy for EGFR Wild Type Non-small Cell Lung Cancer With 4-10 Brain Metastases[NCT02556593]Phase 212 participants (Actual)Interventional2015-09-30Terminated
A Phase 2a Study of the Addition of Temozolomide to a Standard Conditioning Regimen for Autologous Stem Cell Transplantation in Relapsed and Refractory Central Nervous System (CNS) Lymphoma[NCT01235793]Phase 211 participants (Actual)Interventional2010-10-14Terminated (stopped due to The clinical trial was terminated due to poor enrollment)
A Phase II Study of TEMOZOLOMIDE in Advanced Non-Small Cell Lung Cancer With and Without Brain Metastases[NCT00003062]Phase 270 participants (Anticipated)Interventional1997-07-31Completed
A Pilot Study Investigating Neoadjuvant Temozolomide-based Proton Chemoradiotherapy for High-Risk Soft Tissue Sarcomas[NCT00881595]Phase 20 participants (Actual)Interventional2009-02-28Withdrawn (stopped due to No patients accrued since study opened)
Phase II Study of Gamma Knife Radiosurgery and Temozolomide (Temodar) for Newly Diagnosed Brain Metastases[NCT00582075]Phase 225 participants (Actual)Interventional2002-07-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Number of Participants With Adverse Events

Tabulated According to the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0. Summary level. (NCT01638546)
Timeframe: From the start of treatment until 30 days from coming off treatment

InterventionParticipants (Count of Participants)
Arm I (Veliparib and Temozolomide)52
Arm II (Placebo and Temozolomide)45

Overall Response (ORR) by RECIST 1.1 Criteria

Corresponding exact two-sided 95% confidence intervals will be calculated and reported in both arms of the study. Comparisons between treatment arms will be performed using Fisher-exact test. (NCT01638546)
Timeframe: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 4 months

Interventionparticipants (Number)
Arm I (Veliparib and Temozolomide)20
Arm II (Placebo and Temozolomide)6

Overall Survival

Estimated in each treatment group using Kaplan-Meier method. Group comparisons will be performed using log-rank test. (NCT01638546)
Timeframe: From randomization to time of death

Interventionmonths (Median)
Arm I (Veliparib and Temozolomide)8.2
Arm II (Placebo and Temozolomide)7

Progression-free Survival, Calculated as the Proportion of Patients Alive and Without Evidence of Disease

Compared across the two arms using a Fisher exact test. (NCT01638546)
Timeframe: From randomization to time of progression or death, whichever occurs first, assessed at 4 months

Interventionparticipants (Number)
Arm I (Veliparib and Temozolomide)18
Arm II (Placebo and Temozolomide)11

Number of Participants Who Had Brain Metastases

Brain Metastases were defined as radiological evidence of brain metastases on magnetic resonance imaging (MRI). (NCT00632203)
Timeframe: Up to 12 months (as measured from day 1 of cycle 1 of standard first-line systemic chemotherapy)

Interventionparticipants (Number)
Temozolomide Treatment4
Observation3

Overall Survival

The overall survival was analyzed using the Kaplan-Meier method. (NCT00632203)
Timeframe: from Cycle 1 Day 1 of Standard First Line Systemic Therapy to the last time of follow-up

Interventionmonths (Median)
Temozolomide Treatment27.14
Observation22.54

Time to Progression

"The time to progression (per response evaluation criteria in solid tumors [RECIST]) was analyzed using the Kaplan-Meier method.~Definitions of response per RECIST:~Complete Response (CR): Disappearance of all target lesions.~Partial Response (PR): A decrease of at least 30% in the sum of the longest~diameter of target lesions.~Progressive Disease (PD): An increase of at least 20% in the sum of the longest~diameter of target lesions.~Stable Disease (SD): Neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease." (NCT00632203)
Timeframe: from Cycle 1 Day 1 of Standard First Line Systemic Therapy to progression or up to 6 cycles (168 days) of study treatment

Interventionmonths (Median)
Temozolomide Treatment11.70
Observation10.68

Time to Radiological Central Nervous System (CNS) Progression

"Defined as CNS progression as measured by MRI.~Time to CNS progression was analyzed using the Kaplan-Meier method." (NCT00632203)
Timeframe: from Cycle 1 Day 1 of Standard First Line Systemic Therapy to radiological progression or the last known CNS progression-free date

Interventionmonths (Median)
Temozolomide TreatmentNA
ObservationNA

Tolerability of Maintenance Temozolomide

Tolerability was defined as number of participants with any adverse event leading to study discontinuation and/or study drug discontinuation. (NCT00632203)
Timeframe: from Cycle 1 Day 1 of Standard First Line Systemic Therapy to the last time of follow-up (up to 6 cycles (168 days) of study treatment)

Interventionparticipants (Number)
Temozolomide Treatment5
ObservationNA

Safest Dose of Temozolomide for the DRBEAT Regimen

Safety will be assessed using a dose escalation design for temozolomide's use to determine the target dose and also to evaluate any and all acute treatment related toxicities. During the course of patient follow up and therapy, toxicities will be evaluated, particularly as the investigators will be determining the target dose of temozolomide. One of the major criteria for dose limiting toxicity for the study will be any Grade 3 or 4 nonhematologic toxicity from a list of commonly expected toxicities associated with autologous transplantation and temozolomide. (NCT01235793)
Timeframe: One Year

Interventiondose in mg/m^2 (Number)
DRBEAT Regimen773.25

One-year Progression-free Survival and Overall Survival

"Efficacy of the DRBEAT Regimen will be assessed by analysis of~one-year progression-free survival (PFS), defined as the time interval from maximal response from therapy to tumor regrowth, progression*, or death, (*Progression is defined as meeting the response criteria listed in Table 4: Response Criteria for Primary Central Nervous System Lymphoma according to Abrey LE, Batchelor TT, Ferreri AJM et al.)~and~Overall survival, defined as the time interval between the date of transplant and the date of death from any cause." (NCT01235793)
Timeframe: (1) One Year (2) Until date of death from any cause, assessed up to 2 years

InterventionDays (Median)
Progression Free SurvivalOverall Survival
DRBEAT Regimen132564

Overall Survival

(NCT00582075)
Timeframe: 2 years

Interventionweeks (Median)
Radiosurgery 15-24 Gy + Adjuvant Temozolomide31

Percentage of Participants With Distant Brain Failure (DBF) at One Year

Patients developing distant brain failure (DBF) at one year. An approximation method was used to arrive at the reported percentage. (NCT00582075)
Timeframe: 1 years

Interventionpercentage of participants (Number)
Radiosurgery 15-24 Gy + Adjuvant Temozolomide37

Reviews

16 reviews available for temozolomide and Cancer of Lung

ArticleYear
Response and safety of whole-brain radiotherapy plus temozolomide for patients with brain metastases of non-small-cell lung cancer: A meta-analysis.
    Thoracic cancer, 2021, Volume: 12, Issue:23

    Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Combined Modalit

2021
Pulmonary Neuroendocrine Tumors: Adjuvant and Systemic Treatments.
    Current treatment options in oncology, 2020, 08-29, Volume: 21, Issue:11

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bronchial Neoplasms; Capecita

2020
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
    Annales medico-psychologiques, 2021, Volume: 179, Issue:2

    Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli

2021
Combined treatment for non-small cell lung cancer and breast cancer patients with brain metastases with whole brain radiotherapy and temozolomide: a systematic review and meta-analysis.
    Journal of neuro-oncology, 2017, Volume: 135, Issue:2

    Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung

2017
Meta-analysis of whole-brain radiotherapy plus temozolomide compared with whole-brain radiotherapy for the treatment of brain metastases from non-small-cell lung cancer.
    Cancer medicine, 2018, Volume: 7, Issue:4

    Topics: Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Combined Modality Therapy

2018
[Medical treatment of small cell lung cancer: Can we leave the area of cisplatin-etoposide?]
    Bulletin du cancer, 2018, Volume: 105, Issue:10

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Aurora Kinase A; Benzodiazepinones; Dacarb

2018
Extracranial glioblastoma with synchronous metastases in the lung, pulmonary lymph nodes, vertebrae, cervical muscles and epidural space in a young patient - case report and review of literature.
    BMC research notes, 2013, Jul-25, Volume: 6

    Topics: Adult; Antineoplastic Agents, Alkylating; Biopsy; Chemoradiotherapy, Adjuvant; Dacarbazine; Epidural

2013
Immune modulations during chemoimmunotherapy & novel vaccine strategies--in metastatic melanoma and non small-cell lung cancer.
    Danish medical journal, 2013, Volume: 60, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Carcinoma, Non-Small-Cell Lung; Dac

2013
The targeting of indoleamine 2,3 dioxygenase -mediated immune escape in cancer.
    Basic & clinical pharmacology & toxicology, 2015, Volume: 116, Issue:1

    Topics: Antibodies, Monoclonal; Carcinoma, Non-Small-Cell Lung; Dacarbazine; Humans; Immunologic Factors; Im

2015
Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2015, Volume: 26, Issue:8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bronchoscopy; Carboplatin; Carcinoid Heart Disease;

2015
O
    Lung cancer (Amsterdam, Netherlands), 2017, Volume: 107

    Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carcinogenesis; Carcinoma, Non-Small-Cell Lung;

2017
[Carcinoid tumors].
    Orvosi hetilap, 2010, Nov-14, Volume: 151, Issue:46

    Topics: 3-Iodobenzylguanidine; Antineoplastic Agents; Biomarkers, Tumor; Bronchial Neoplasms; Carcinoid Tumo

2010
Temozolomide and unusual indications: review of literature.
    Cancer treatment reviews, 2013, Volume: 39, Issue:2

    Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Humans; Lung Neoplasms; Melanoma; N

2013
[Therapy of malignant melanoma at the stage of distant metastasis].
    Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 2004, Volume: 55, Issue:2

    Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineo

2004
[Chemotherapy for brain metastases].
    Nihon rinsho. Japanese journal of clinical medicine, 2005, Volume: 63 Suppl 9

    Topics: Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Brain Neoplasm

2005
Temozolomide for treating brain metastases.
    Seminars in oncology, 2001, Volume: 28, Issue:4 Suppl 13

    Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Chemothera

2001

Trials

28 trials available for temozolomide and Cancer of Lung

ArticleYear
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
    Annales medico-psychologiques, 2021, Volume: 179, Issue:2

    Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli

2021
Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018, 08-10, Volume: 36, Issue:23

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemother

2018
Refining the selection of patients with metastatic colorectal cancer for treatment with temozolomide using proteomic analysis of O6-methylguanine-DNA-methyltransferase.
    European journal of cancer (Oxford, England : 1990), 2019, Volume: 107

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Colorectal Neoplasms;

2019
Refining the selection of patients with metastatic colorectal cancer for treatment with temozolomide using proteomic analysis of O6-methylguanine-DNA-methyltransferase.
    European journal of cancer (Oxford, England : 1990), 2019, Volume: 107

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Colorectal Neoplasms;

2019
Refining the selection of patients with metastatic colorectal cancer for treatment with temozolomide using proteomic analysis of O6-methylguanine-DNA-methyltransferase.
    European journal of cancer (Oxford, England : 1990), 2019, Volume: 107

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Colorectal Neoplasms;

2019
Refining the selection of patients with metastatic colorectal cancer for treatment with temozolomide using proteomic analysis of O6-methylguanine-DNA-methyltransferase.
    European journal of cancer (Oxford, England : 1990), 2019, Volume: 107

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Colorectal Neoplasms;

2019
O6-methylguanine-DNA methyltransferase (MGMT) status in neuroendocrine tumors: a randomized phase II study (MGMT-NET).
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2019, Volume: 51, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Clinical Trials, Phase II as Topic; DNA Methylation;

2019
Temozolomide added to whole brain radiotherapy in patients with multiple brain metastases of non-small-cell lung cancer: a multicentric Austrian phase II study.
    Wiener klinische Wochenschrift, 2013, Volume: 125, Issue:15-16

    Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Austria; Brain Neoplasms; Carcinoma, Non-Small-Cell

2013
Whole brain reirradiation and concurrent temozolomide in patients with brain metastases.
    Journal of neuro-oncology, 2014, Volume: 118, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Breast Neoplasms; Carcinoma; Carcin

2014
Strategies to prevent brain metastasis in high-risk non-small-cell lung cancer: lessons learned from a randomized study of maintenance temozolomide versus observation.
    Clinical lung cancer, 2014, Volume: 15, Issue:6

    Topics: Aged; Brain; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Dacarbazine; Early Termination of Clin

2014
Phase 2 trial of temozolomide using protracted low-dose and whole-brain radiotherapy for nonsmall cell lung cancer and breast cancer patients with brain metastases.
    Cancer, 2008, Nov-01, Volume: 113, Issue:9

    Topics: Aged; Antineoplastic Agents, Alkylating; Bone Marrow; Brain Neoplasms; Breast Neoplasms; Carcinoma,

2008
Continuous administration of daily low-dose temozolomide in pretreated patients with advanced non-small cell lung cancer: a phase II study.
    Oncology, 2009, Volume: 76, Issue:2

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Ce

2009
Dose-dense temozolomide regimen for the treatment of brain metastases from melanoma, breast cancer, or lung cancer not amenable to surgery or radiosurgery: a multicenter phase II study.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2010, Volume: 21, Issue:3

    Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung

2010
Whole-brain radiation therapy plus concomitant temozolomide for the treatment of brain metastases from non-small-cell lung cancer: a randomized, open-label phase II study.
    Clinical lung cancer, 2010, Volume: 11, Issue:3

    Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Com

2010
Phase I dose finding study of carboplatin, paclitaxel, and temozolomide in advanced solid tumors.
    Melanoma research, 2011, Volume: 21, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cohort Studies; Dacarbazin

2011
Outcome, quality of life and cognitive function of patients with brain metastases from non-small cell lung cancer treated with whole brain radiotherapy combined with gefitinib or temozolomide. A randomised phase II trial of the Swiss Group for Clinical Ca
    European journal of cancer (Oxford, England : 1990), 2012, Volume: 48, Issue:3

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Brief Psychiatric Rating Scale; Car

2012
Outcome, quality of life and cognitive function of patients with brain metastases from non-small cell lung cancer treated with whole brain radiotherapy combined with gefitinib or temozolomide. A randomised phase II trial of the Swiss Group for Clinical Ca
    European journal of cancer (Oxford, England : 1990), 2012, Volume: 48, Issue:3

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Brief Psychiatric Rating Scale; Car

2012
Outcome, quality of life and cognitive function of patients with brain metastases from non-small cell lung cancer treated with whole brain radiotherapy combined with gefitinib or temozolomide. A randomised phase II trial of the Swiss Group for Clinical Ca
    European journal of cancer (Oxford, England : 1990), 2012, Volume: 48, Issue:3

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Brief Psychiatric Rating Scale; Car

2012
Outcome, quality of life and cognitive function of patients with brain metastases from non-small cell lung cancer treated with whole brain radiotherapy combined with gefitinib or temozolomide. A randomised phase II trial of the Swiss Group for Clinical Ca
    European journal of cancer (Oxford, England : 1990), 2012, Volume: 48, Issue:3

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Brief Psychiatric Rating Scale; Car

2012
Phase II trial of temozolomide in patients with relapsed sensitive or refractory small cell lung cancer, with assessment of methylguanine-DNA methyltransferase as a potential biomarker.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2012, Feb-15, Volume: 18, Issue:4

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Dacarbazine; DNA Meth

2012
Phase II trial of temozolomide for leptomeningeal metastases in patients with solid tumors.
    Journal of neuro-oncology, 2012, Volume: 109, Issue:1

    Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Da

2012
A phase 3 trial of whole brain radiation therapy and stereotactic radiosurgery alone versus WBRT and SRS with temozolomide or erlotinib for non-small cell lung cancer and 1 to 3 brain metastases: Radiation Therapy Oncology Group 0320.
    International journal of radiation oncology, biology, physics, 2013, Apr-01, Volume: 85, Issue:5

    Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carcinoma, Non-Smal

2013
Temozolomide in patients with advanced non-small cell lung cancer with and without brain metastases. a phase II study of the EORTC Lung Cancer Group (08965).
    European journal of cancer (Oxford, England : 1990), 2003, Volume: 39, Issue:9

    Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Dac

2003
Temozolomide and interferon alpha 2b in metastatic melanoma stage IV.
    The British journal of dermatology, 2004, Volume: 151, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Drug Administration Schedu

2004
Temozolomide (TMZ) combined with cisplatin (CDDP) in patients with brain metastases from solid tumors: a Hellenic Cooperative Oncology Group (HeCOG) Phase II study.
    Journal of neuro-oncology, 2005, Volume: 71, Issue:1

    Topics: Adult; Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Brea

2005
Oral temozolomide in heavily pre-treated brain metastases from non-small cell lung cancer: phase II study.
    Lung cancer (Amsterdam, Netherlands), 2005, Volume: 50, Issue:2

    Topics: Administration, Oral; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carcinoma, Non-Small

2005
A phase II trial of temozolomide as a 6-week, continuous, oral schedule in patients with advanced soft tissue sarcoma: a study by the Spanish Group for Research on Sarcomas.
    Cancer, 2005, Oct-15, Volume: 104, Issue:8

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Drug Administrati

2005
Vinorelbine combined with a protracted course of temozolomide for recurrent brain metastases: a phase I trial.
    Journal of neuro-oncology, 2006, Volume: 78, Issue:3

    Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Co

2006
Phase II trial of temozolomide and cisplatin followed by whole brain radiotherapy in non-small-cell lung cancer patients with brain metastases: a GLOT-GFPC study.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2006, Volume: 17, Issue:9

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Non-Small-C

2006
Alternating chemo-immunotherapy with temozolomide and low-dose interleukin-2 in patients with metastatic melanoma.
    Melanoma research, 2006, Volume: 16, Issue:4

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Fema

2006
Phase II trial of temozolomide and irinotecan as second-line treatment for advanced non-small cell lung cancer.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2006, Volume: 1, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cam

2006
Phase II study of temozolomide and concomitant whole-brain radiotherapy in patients with brain metastases from solid tumors.
    Onkologie, 2007, Volume: 30, Issue:7

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Breast Neoplasms; Carci

2007
A phase II trial of temozolomide for patients with recurrent or progressive brain metastases.
    Journal of neuro-oncology, 2001, Volume: 53, Issue:3

    Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Dac

2001
Effect of temozolomide on central nervous system relapse in patients with advanced melanoma.
    Melanoma research, 2002, Volume: 12, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Case-Control Stu

2002

Other Studies

66 other studies available for temozolomide and Cancer of Lung

ArticleYear
Translesion DNA synthesis mediates acquired resistance to olaparib plus temozolomide in small cell lung cancer.
    Science advances, 2022, 05-13, Volume: 8, Issue:19

    Topics: Cell Line, Tumor; DNA; DNA Damage; DNA Replication; Humans; Lung Neoplasms; Phthalazines; Piperazine

2022
Are anaplastic lymphoma kinase (ALK) and O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation driver biomarkers of pulmonary neuroendocrine tumors (NETs) and carcinomas (NECs)?
    Oncotarget, 2022, Volume: 13

    Topics: Anaplastic Lymphoma Kinase; Biomarkers; Carcinoid Tumor; Carcinoma, Neuroendocrine; DNA; DNA Methyla

2022
Checkpoint Inhibitor Immunotherapy to Treat Temozolomide-Associated Hypermutation in Advanced Atypical Carcinoid Tumor of the Lung.
    JCO precision oncology, 2022, Volume: 6

    Topics: Carcinoid Tumor; Humans; Immunotherapy; Lung Neoplasms; Temozolomide

2022
A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2023, 02-16, Volume: 29, Issue:4

    Topics: Humans; Lung Neoplasms; Neuroendocrine Tumors; Nivolumab; Progression-Free Survival; Temozolomide

2023
Treatment of inoperable large cell neuroendocrine lung cancer with single agent temozolomide.
    Acta oncologica (Stockholm, Sweden), 2023, Volume: 62, Issue:12

    Topics: Carcinoma, Large Cell; Carcinoma, Neuroendocrine; Dacarbazine; Humans; Lung Neoplasms; Neuroendocrin

2023
Capecitabine and Temozolomide in Patients with Advanced Pulmonary Carcinoid Tumours.
    Neuroendocrinology, 2020, Volume: 110, Issue:5

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Comb

2020
Temozolomide plus PARP Inhibition in Small-Cell Lung Cancer: Could Patient-Derived Xenografts Accelerate Discovery of Biomarker Candidates?
    Cancer discovery, 2019, Volume: 9, Issue:10

    Topics: Animals; Biomarkers; Cell Line, Tumor; Heterografts; Humans; Lung Neoplasms; Neoplasm Recurrence, Lo

2019
Chemotherapy combined with bevacizumab for the treatment of advanced lung adenocarcinoma cancer harboring EGFR-ANXA2, EGFR-RAD51, ATR and BRCA2 mutations: A case report.
    Thoracic cancer, 2020, Volume: 11, Issue:2

    Topics: Adenocarcinoma of Lung; Adult; Annexin A2; Antineoplastic Combined Chemotherapy Protocols; Ataxia Te

2020
Temozolomide plus whole brain radiotherapy for the treatment of non-small-cell lung cancer patients with brain metastases: A protocol of an updated systematic review and meta-analysis.
    Medicine, 2020, Volume: 99, Issue:5

    Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neo

2020
Sensitivity of Mesothelioma Cells to PARP Inhibitors Is Not Dependent on BAP1 but Is Enhanced by Temozolomide in Cells With High-Schlafen 11 and Low-O6-methylguanine-DNA Methyltransferase Expression.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2020, Volume: 15, Issue:5

    Topics: Cell Line, Tumor; Guanine; Humans; Lung Neoplasms; Mesothelioma; O(6)-Methylguanine-DNA Methyltransf

2020
The Association of BAP1 Loss-of-Function With the Defect in Homologous Recombination Repair and Sensitivity to PARP-Targeted Therapy.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2020, Volume: 15, Issue:6

    Topics: DNA; DNA Repair; Guanine; Humans; Lung Neoplasms; Mesothelioma; Methyltransferases; Poly(ADP-ribose)

2020
Response to Letter to the Editor by Yang et al.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2020, Volume: 15, Issue:6

    Topics: DNA; Guanine; Humans; Lung Neoplasms; Mesothelioma; Methyltransferases; Poly(ADP-ribose) Polymerase

2020
Deep and Durable Response to Nivolumab and Temozolomide in Small-Cell Lung Cancer Associated With an Early Decrease in Myeloid-Derived Suppressor Cells.
    Clinical lung cancer, 2021, Volume: 22, Issue:4

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Humans; Lung Neoplasms; Male; Myeloid-Derived

2021
Complete response of radioresistant brain metastases from non-small cell lung cancer with temozolomide: A case report and literature review.
    Medicine, 2020, Dec-18, Volume: 99, Issue:51

    Topics: Adenocarcinoma of Lung; Antineoplastic Agents, Alkylating; Brain Neoplasms; Female; Humans; Lung Neo

2020
Correlation between MGMT promoter methylation and response to temozolomide-based therapy in neuroendocrine neoplasms: an observational retrospective multicenter study.
    Endocrine, 2018, Volume: 60, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Fe

2018
Temozolomide-perillyl alcohol conjugate downregulates O
    Cell death & disease, 2018, 02-09, Volume: 9, Issue:2

    Topics: A549 Cells; Antineoplastic Agents, Alkylating; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; DNA

2018
Effectiveness of temozolomide combined with whole brain radiotherapy for non-small cell lung cancer brain metastases.
    Thoracic cancer, 2018, Volume: 9, Issue:9

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Brain Neoplasms; Carcinoma,

2018
SLFN11: a new synthetic lethal target?
    Nature reviews. Clinical oncology, 2018, Volume: 15, Issue:9

    Topics: Benzimidazoles; Double-Blind Method; Humans; Lung Neoplasms; Nuclear Proteins; Small Cell Lung Carci

2018
Temozolomide-Perillyl alcohol conjugate impairs Mitophagy flux by inducing lysosomal dysfunction in non-small cell lung Cancer cells and sensitizes them to irradiation.
    Journal of experimental & clinical cancer research : CR, 2018, Oct-16, Volume: 37, Issue:1

    Topics: Antineoplastic Agents, Alkylating; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Humans; Lung Ne

2018
Is SLFN11 a Promising Predictive Biomarker of Poly (ADP-ribose) Polymerase Inhibitor Sensitivity in Small-Cell Lung Cancer? Not Yet!
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019, 01-20, Volume: 37, Issue:3

    Topics: Adenosine Diphosphate; Benzimidazoles; Biomarkers; Double-Blind Method; Humans; Lung Neoplasms; Nucl

2019
Reply to F. Liang.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019, 01-20, Volume: 37, Issue:3

    Topics: Benzimidazoles; Double-Blind Method; Humans; Lung Neoplasms; Temozolomide

2019
The clinical conundrum of managing relapsed small cell lung cancer.
    Cancer, 2019, 04-01, Volume: 125, Issue:7

    Topics: Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplas

2019
Successful treatment with temozolomide in an elderly woman with advanced pulmonary large-cell neuroendocrine carcinoma: A case report.
    Medicine, 2018, Volume: 97, Issue:51

    Topics: Aged; Antineoplastic Agents, Alkylating; Carcinoma, Large Cell; Carcinoma, Neuroendocrine; Female; H

2018
Chemotherapy-induced secondary pneumothorax.
    Archivos de bronconeumologia, 2014, Volume: 50, Issue:1

    Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizuma

2014
Statistical and practical considerations for clinical evaluation of predictive biomarkers.
    Journal of the National Cancer Institute, 2013, Nov-20, Volume: 105, Issue:22

    Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Dac

2013
Successful administration of ipilimumab to two kidney transplantation patients with metastatic melanoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Jul-01, Volume: 32, Issue:19

    Topics: Administration, Oral; Aged; Antibodies, Monoclonal; Antineoplastic Agents; Dacarbazine; Drug Adminis

2014
[Management of patients with metastatic cutaneous melanoma: French national guidelines. French National Cancer Institute].
    Annales de dermatologie et de venereologie, 2014, Volume: 141, Issue:2

    Topics: Antibodies, Monoclonal; Antineoplastic Agents; Bone Neoplasms; Brain Neoplasms; Combined Modality Th

2014
Whole brain radiation therapy followed by intensity-modulated boosting treatment combined with concomitant temozolomide for brain metastases from non-small-cell lung cancer.
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2014, Volume: 16, Issue:11

    Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Com

2014
Trial of a 5-day dosing regimen of temozolomide in patients with relapsed small cell lung cancers with assessment of methylguanine-DNA methyltransferase.
    Lung cancer (Amsterdam, Netherlands), 2014, Volume: 86, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Dacarbazine; Drug Administration

2014
New dry powders for inhalation containing temozolomide-based nanomicelles for improved lung cancer therapy.
    International journal of oncology, 2015, Volume: 47, Issue:3

    Topics: Administration, Inhalation; Animals; Antineoplastic Agents; Cell Proliferation; Chemistry, Pharmaceu

2015
Combined therapy of oncolytic adenovirus and temozolomide enhances lung cancer virotherapy in vitro and in vivo.
    Virology, 2016, Volume: 487

    Topics: Adenoviridae; Adenoviridae Infections; Adenovirus E1B Proteins; Animals; Antineoplastic Agents, Alky

2016
Intra-arterial administration improves temozolomide delivery and efficacy in a model of intracerebral metastasis, but has unexpected brain toxicity.
    Journal of neuro-oncology, 2016, Volume: 126, Issue:3

    Topics: Animals; Antineoplastic Agents, Alkylating; Blood-Brain Barrier; Brain Neoplasms; Dacarbazine; Drug

2016
Temozolomide-perillyl alcohol conjugate induced reactive oxygen species accumulation contributes to its cytotoxicity against non-small cell lung cancer.
    Scientific reports, 2016, Mar-07, Volume: 6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line

2016
Modulation of Pathways Underlying Distinct Cell Death Mechanisms in Two Human Lung Cancer Cell Lines in Response to SN1 Methylating Agents Treatment.
    PloS one, 2016, Volume: 11, Issue:7

    Topics: A549 Cells; Alkylating Agents; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Death; Cell L

2016
The efficacy and roles of combining temozolomide with whole brain radiotherapy in protection neurocognitive function and improvement quality of life of non-small-cell lung cancer patients with brain metastases.
    BMC cancer, 2017, 01-10, Volume: 17, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms;

2017
Antitumor activity of intratracheal inhalation of temozolomide (TMZ) loaded into gold nanoparticles and/or liposomes against urethane-induced lung cancer in BALB/c mice.
    Drug delivery, 2017, Volume: 24, Issue:1

    Topics: Administration, Inhalation; Animals; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Dacarbazi

2017
Homogeneous MGMT immunoreactivity correlates with an unmethylated MGMT promoter status in brain metastases of various solid tumors.
    PloS one, 2009, Volume: 4, Issue:3

    Topics: Alkylating Agents; Brain Neoplasms; Breast Neoplasms; Dacarbazine; DNA Methylation; DNA Modification

2009
Cell cycle effects and increased adduct formation by temozolomide enhance the effect of cytotoxic and targeted agents in lung cancer cell lines.
    Journal of chemotherapy (Florence, Italy), 2009, Volume: 21, Issue:3

    Topics: Animals; Antineoplastic Agents, Alkylating; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, T

2009
FEN1 is overexpressed in testis, lung and brain tumors.
    Anticancer research, 2009, Volume: 29, Issue:7

    Topics: Antineoplastic Agents; Apoptosis; Base Sequence; Brain Neoplasms; Cisplatin; Dacarbazine; Flap Endon

2009
O(6)-Methylguanine-DNA methyltransferase expression and prognostic value in brain metastases of lung cancers.
    Lung cancer (Amsterdam, Netherlands), 2010, Volume: 68, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms;

2010
p53-Mediated down-regulation of the human DNA repair gene O6-methylguanine-DNA methyltransferase (MGMT) via interaction with Sp1 transcription factor.
    Anticancer research, 2009, Volume: 29, Issue:10

    Topics: Antineoplastic Agents, Alkylating; Colonic Neoplasms; Consensus Sequence; Dacarbazine; DNA Repair; D

2009
In vivo assessment of temozolomide local delivery for lung cancer inhalation therapy.
    European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2010, Mar-18, Volume: 39, Issue:5

    Topics: Administration, Inhalation; Animals; Antineoplastic Agents; Cell Line, Tumor; Chromatography, High P

2010
Leptomeningeal metastases from small cell lung cancer responsive to temozolomide therapy.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2010, Volume: 5, Issue:10

    Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Humans; Lung Neoplasms; Mal

2010
Temozolomide-based dry powder formulations for lung tumor-related inhalation treatment.
    Pharmaceutical research, 2011, Volume: 28, Issue:4

    Topics: Administration, Inhalation; Antineoplastic Agents, Alkylating; Dacarbazine; Drug Compounding; Drug D

2011
The A/G allele of rs16906252 predicts for MGMT methylation and is selectively silenced in premalignant lesions from smokers and in lung adenocarcinomas.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Apr-01, Volume: 17, Issue:7

    Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Agents, Alkylating; beta-Galacto

2011
[Protracted low-dose temozolomide combined with concomitant whole brain radiotherapy for brain metastases from non-small cell lung cancer].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2011, Volume: 33, Issue:10

    Topics: Adult; Aged; Agranulocytosis; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carcinoma, Non-Sma

2011
Mitogen-activated protein kinase (MEK/ERK) inhibition sensitizes cancer cells to centromere-associated protein E inhibition.
    International journal of cancer, 2013, Feb-01, Volume: 132, Issue:3

    Topics: Antineoplastic Agents; Apoptosis; Benzamides; Biomarkers, Tumor; Bridged Bicyclo Compounds, Heterocy

2013
Use of temozolomide with other cytotoxic chemotherapy in the treatment of patients with recurrent brain metastases from lung cancer.
    The oncologist, 2003, Volume: 8, Issue:1

    Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms;

2003
Chemopotentiation of temozolomide, irinotecan, and cisplatin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor.
    Molecular cancer therapeutics, 2003, Volume: 2, Issue:4

    Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic

2003
Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361.
    Journal of the National Cancer Institute, 2004, Jan-07, Volume: 96, Issue:1

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azulenes; Benzodiaze

2004
Potentiation of cytotoxic drug activity in human tumour cell lines, by amine-substituted 2-arylbenzimidazole-4-carboxamide PARP-1 inhibitors.
    Bioorganic & medicinal chemistry letters, 2004, May-17, Volume: 14, Issue:10

    Topics: Amides; Animals; Antineoplastic Agents; Benzimidazoles; Cell Line, Tumor; Cell Proliferation; Colore

2004
Response to temozolomide in second-line treatment of recurrent nonsmall cell lung carcinoma: case report.
    Cancer investigation, 2005, Volume: 23, Issue:2

    Topics: Administration, Oral; Antineoplastic Agents, Alkylating; Carcinoma, Non-Small-Cell Lung; Dacarbazine

2005
Primary malignant melanoma of the lung: a case report and review of the literature.
    Clinical lung cancer, 2006, Volume: 7, Issue:4

    Topics: Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Dacarbazine; Fluorodeoxyglucose F18; Humans; L

2006
Cardiac metastasis from uterine leiomyosarcoma.
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2006, Volume: 8, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dacarbazine; Deoxycytidin

2006
Temozolomide as prophylaxis for brain metastasis in non-small cell lung cancer.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2006, Volume: 1, Issue:7

    Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin;

2006
Radiochemotherapy for brain metastasis: how to define a role for temozolomide.
    Onkologie, 2007, Volume: 30, Issue:7

    Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung

2007
Predictors of distant brain recurrence for patients with newly diagnosed brain metastases treated with stereotactic radiosurgery alone.
    International journal of radiation oncology, biology, physics, 2008, Jan-01, Volume: 70, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Breast Neoplasms

2008
Marked response to a cisplatin/docetaxel/temozolomide combination in a heavily pretreated patient with metastatic large cell neuroendocrine lung carcinoma.
    Anti-cancer drugs, 2007, Volume: 18, Issue:10

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Neuroendocrine; Ci

2007
A rare case of melanoma recurring as subcutaneous metastatic melanoma with overlying ecchymoses.
    Archives of dermatology, 2008, Volume: 144, Issue:4

    Topics: Aged, 80 and over; Antineoplastic Agents, Alkylating; Biopsy; Dacarbazine; Ecchymosis; Female; Human

2008
Intracellular Localization and intercellular heterogeneity of the human DNA repair protein O(6)-methylguanine-DNA methyltransferase.
    Cancer chemotherapy and pharmacology, 1996, Volume: 37, Issue:6

    Topics: Animals; Cell Compartmentation; Cell Nucleus; Cytoplasm; Dacarbazine; DNA Repair; Enzyme Inhibitors;

1996
Activity of temozolomide against human tumor colony-forming units.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 1997, Volume: 3, Issue:10

    Topics: Adrenal Gland Neoplasms; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms;

1997
Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2000, Volume: 6, Issue:7

    Topics: Antineoplastic Agents; Breast Neoplasms; Cell Division; Cell Survival; Colonic Neoplasms; Dacarbazin

2000
Treatment of brain metastases of malignant melanoma with temozolomide.
    The New England journal of medicine, 2001, Aug-23, Volume: 345, Issue:8

    Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Humans; Lung Neoplasms; Magnetic Re

2001
Antitumour imidazotetrazines XXVIII 3-methyladenine DNA glycosylase activity in cell lines sensitive and resistant to temozolomide.
    Cancer letters, 1992, Apr-15, Volume: 63, Issue:2

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Burkitt Lymphoma; Cell Line; Cell Survival; Chromato

1992
Antitumor imidazotetrazines--XV. Role of guanine O6 alkylation in the mechanism of cytotoxicity of imidazotetrazinones.
    Biochemical pharmacology, 1987, Feb-15, Volume: 36, Issue:4

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cell Line; Chlorambucil; Colonic Neoplasms; Dacarbaz

1987
Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine.
    Cancer research, 1987, Nov-15, Volume: 47, Issue:22

    Topics: Animals; Antineoplastic Agents; Dacarbazine; Imidazoles; Lung Neoplasms; Male; Melanoma, Experimenta

1987
Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine.
    Cancer research, 1987, Nov-15, Volume: 47, Issue:22

    Topics: Animals; Antineoplastic Agents; Dacarbazine; Imidazoles; Lung Neoplasms; Male; Melanoma, Experimenta

1987
Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine.
    Cancer research, 1987, Nov-15, Volume: 47, Issue:22

    Topics: Animals; Antineoplastic Agents; Dacarbazine; Imidazoles; Lung Neoplasms; Male; Melanoma, Experimenta

1987
Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine.
    Cancer research, 1987, Nov-15, Volume: 47, Issue:22

    Topics: Animals; Antineoplastic Agents; Dacarbazine; Imidazoles; Lung Neoplasms; Male; Melanoma, Experimenta

1987